An observational study into the maintenance of seroprotection against Meningococcal serogroup C disease throughout childhood following a single dose of a conjugated Meningococcal serogroup C vaccine administered to toddlers - Understanding the persistence of immunity after MenC Vaccines

• Conditions: Active immunisation of children for the prevention of invasive diseases caused by Neisseria meningitidis serogroup C; MedDRA version: 12.1Level: LLTClassification code 10028911Term: Neisseria meningitidis infection NOS

• Registration Number: EUCTR2010-019091-78-GB
• Lead Sponsor: niversity of Oxford

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04-16
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

•Participant whose parent is willing and able to give informed consent for participation in the study.
•Participant who gives assent for participation in the study.
•Male or Female, aged 11 to 13 years.
•Known to be free from medical problems as determined by a medical history and clinical assessment
•Participated in the University of Oxford clinical trial: U01-Td5I-303/ C01.183

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•History of invasive meningococcal C disease
•Any vaccination against MenC disease with the exception of a single dose in 2000 during the nationwide MenC immunisation campaign
•Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection.
•Major congenital defects or serious chronic illness

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified